8,111 Shares in Boston Scientific Corporation $BSX Bought by Ninety One SA Pty Ltd

18 Apr 2026, 08:06 by Scott Moore · The Cerbat Gem

Ninety One SA Pty Ltd purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 8,111 shares of the medical equipment provider’s stock, valued at approximately $773,000.

Other institutional investors have also bought and sold shares of the company. Financial Consulate Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. United Community Bank grew its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Finally, Colonial Trust Co SC grew its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by company insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Analysts are increasingly bullish, citing expectations for ~30% year‑over‑year growth in 2026 and constructive analyst commentary that supports upside to BSX’s earnings trajectory. Analysts Bullish on Boston Scientific (BSX)
Positive Sentiment: Zacks previews point to robust cardiovascular momentum and steady MedSurg growth heading into Q1 results, implying potential upside to revenue and EPS vs. consensus if procedure trends hold. Will Robust Cardiovascular Performance Fuel BSX’s Q1 Earnings?
Positive Sentiment: Boston Scientific is investing $88.4M to expand R&D operations in Ireland — a sign of continued product development and investment in innovation that supports medium‑term growth prospects. Boston Scientific invests $88.4M to expand R&D in Ireland
Neutral Sentiment: Zacks also published a deeper Q1 preview on key operational metrics investors should watch (procedure volumes, segment mix, product cadence) that could swing reactions to the print beyond headline revenue/EPS. Boston Scientific (BSX) Q1 Earnings Preview
Neutral Sentiment: Recent pieces revisiting BSX’s valuation and the impact of the Penumbra acquisition provide context on multiples and longer‑term returns; useful for investors framing position sizing but less likely to move intraday trading. A Look At Boston Scientific (BSX) Valuation
Negative Sentiment: Multiple law firms have issued investor alerts and a class action has been filed alleging securities‑law violations for the July 23, 2025–Feb 3, 2026 period. These coordinated filings and lead‑plaintiff solicitations (with a May 4 deadline cited by several firms) are a near‑term headline risk that can pressure the stock or increase legal expenses/uncertainty. Representative notices and filings: PR Newswire: Shareholders Opportunity to Lead Securities Fraud Lawsuit Bronstein, Gewirtz & Grossman Class Action Notice Faruqi & Faruqi Deadline Reminder

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent research reports. Truist Financial decreased their price objective on Boston Scientific from $92.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday. Canaccord Genuity Group cut their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Royal Bank Of Canada restated an “outperform” rating and set a $115.00 price target on shares of Boston Scientific in a report on Monday, March 30th. Barclays lowered their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. Finally, Robert W. Baird dropped their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $102.82.

Get Our Latest Analysis on BSX

Boston Scientific Stock Up 1.4%

Shares of NYSE:BSX opened at $64.28 on Friday. The firm has a market capitalization of $95.53 billion, a PE ratio of 33.13, a price-to-earnings-growth ratio of 0.98 and a beta of 0.78. The business has a 50 day simple moving average of $69.60 and a two-hundred day simple moving average of $86.96. Boston Scientific Corporation has a 1 year low of $60.59 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Five stocks we like better than Boston Scientific